Protocol Ledger

NCT05167825 · Phase III · COMPLETED

A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension

Interventional Phase III clinical trial protocol NCT05167825 sponsored by Johnson & Johnson / Janssen in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-14 Enrollment: 7 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05167825
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)7 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05167825
Protocol FieldVerified Registry Value
NCT IdentifierNCT05167825
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment7 participants (ACTUAL)
Registered Start Date2022-11-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05167825
Hospital Research SiteLocationSite Profile
Okayama University HospitalOkayama, JapanOpen Hospital Dossier ->
Hokkaido University HospitalSapporo, JapanOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI